Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
29 Sep 2021 07:30 AM
RNS
Interim Results for the 6months ended 30 June 2021
29 Sep 2021 07:00 AM
RNS
Corporate Update
22 Sep 2021 04:41 PM
RNS
Second Price Monitoring Extn
22 Sep 2021 04:36 PM
RNS
Price Monitoring Extension
24 Aug 2021 11:07 AM
RNS
Director/PDMR Shareholding
20 Aug 2021 04:40 PM
RNS
Second Price Monitoring Extn
20 Aug 2021 04:35 PM
RNS
Price Monitoring Extension
19 Aug 2021 04:35 PM
RNS
Price Monitoring Extension
17 Aug 2021 08:50 AM
RNS
Notification of Major Holdings
12 Aug 2021 07:00 AM
RNS
FDA approves the LupzuorT PK study
10 Aug 2021 04:40 PM
RNS
Second Price Monitoring Extn
10 Aug 2021 04:35 PM
RNS
Price Monitoring Extension
30 Jul 2021 07:00 AM
RNS
Board Changes
16 Jul 2021 07:00 AM
RNS
Board Appointment
28 Jun 2021 12:27 PM
RNS
2021 RESULT OF ANNUAL GENERAL MEETING -REPLACEMENT
28 Jun 2021 11:03 AM
RNS
2021 RESULT OF ANNUAL GENERAL MEETING
24 Jun 2021 04:41 PM
RNS
Second Price Monitoring Extn
24 Jun 2021 04:36 PM
RNS
Price Monitoring Extension
24 Jun 2021 07:00 AM
RNS
Update: LupzuorT PK study
02 Jun 2021 07:00 AM
RNS
Notice of AGM and posting of Report & Accounts
24 May 2021 07:00 AM
RNS
Director Retirement
29 Apr 2021 04:35 PM
RNS
Price Monitoring Extension
29 Apr 2021 07:00 AM
RNS
Final Results
16 Apr 2021 04:41 PM
RNS
Second Price Monitoring Extn
16 Apr 2021 04:36 PM
RNS
Price Monitoring Extension
25 Feb 2021 04:41 PM
RNS
Second Price Monitoring Extn
25 Feb 2021 04:35 PM
RNS
Price Monitoring Extension
09 Feb 2021 07:00 AM
RNS
Update- scheduled Phase 3 trials in lupus patients
18 Jan 2021 07:00 AM
RNS
Appointment of Company Secretary
04 Jan 2021 07:00 AM
RNS
Holding(s) in Company
02 Dec 2020 07:00 AM
RNS
IMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021
30 Nov 2020 07:00 AM
RNS
Total Share Capital Notification
26 Nov 2020 07:00 AM
RNS
Grant of Share Options & PDMR dealing
24 Nov 2020 07:00 AM
RNS
Conversion of Convertible Security
23 Nov 2020 07:00 AM
RNS
Conversion of Convertible Security
20 Nov 2020 07:00 AM
RNS
Update : FDA confirms 4 Dec for Type 'A' meeting
18 Nov 2020 07:00 AM
RNS
Total Share Capital Notification - Replacement
10 Nov 2020 07:00 AM
RNS
Update on submission to the FDA
30 Sep 2020 07:01 AM
RNS
Total Share Capital Notification
30 Sep 2020 07:00 AM
RNS
Interim Results
29 Sep 2020 07:00 AM
RNS
Share Subscription into Incanthera plc
22 Sep 2020 07:00 AM
RNS
Repayment of Convertible Security
11 Sep 2020 07:59 AM
RNS
Update on submission to the FDA
10 Sep 2020 10:59 AM
RNS
Conversion of Convertible Security
09 Sep 2020 01:45 PM
RNS
Conversion of Convertible Security
08 Sep 2020 03:49 PM
RNS
Holding(s) in Company
08 Sep 2020 09:00 AM
RNS
Director/PDMR Shareholding / TR -1
07 Sep 2020 07:02 AM
RNS
Placing - update; related party transaction)
03 Sep 2020 07:00 AM
RNS
Conversion of Convertible Security
02 Sep 2020 07:00 AM
RNS
Placing to raise £6.5 million

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100